Vyome (HIND) Stock Price, News & Analysis

Company Overview

Vyome is a biotechnology company focused on developing therapies for dermatological conditions. Its research programs are centered on skin diseases involving inflammation, microbial imbalance and antibiotic resistance, with the goal of creating targeted treatments for patients who have limited options.

The company’s pipeline has included topical therapies for acne and other inflammatory skin disorders. Among its reported programs is VB-1953, an investigational topical treatment designed to address acne-causing bacteria while potentially reducing concerns associated with conventional broad-spectrum antibiotics. Vyome’s drug candidates remain subject to clinical development and regulatory review.

Vyome was established as a dermatology-focused biotechnology business with operations and research activities associated with the United States and India. Publicly available information about its current leadership, commercial products and geographic operations is limited, and the company’s development programs may change as clinical and regulatory work progresses.

Key Stats

• Today's Range: $2.01 to $2.09
• 50-Day Range: $1.91 to $2.32
• 52-Week Range: $1.75 to $6.56
• Volume: 7,586 shs
• Average Volume: 22,158 shs
• Market Capitalization: $14.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Hold

Vyome Stock Analysis - MarketRank™

Vyome scored higher than 52% of companies evaluated by MarketBeat, and ranked 509th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Vyome has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vyome has a consensus price target of $3.50, representing about 67.5% upside from its current price of $2.09.

Amount of Analyst Coverage

Vyome has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vyome is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vyome is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vyome has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.56% of the float of Vyome has been sold short.

Short Interest Ratio / Days to Cover

Vyome has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vyome has recently increased by 21.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vyome does not currently pay a dividend.

Dividend Growth

Vyome does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.23

News Sentiment

Vyome has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vyome this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Vyome to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vyome insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.00% of the stock of Vyome is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.06% of the stock of Vyome is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HIND
• CIK: 1427570
• Web: vyometx.com
• Phone: (949) 429-6680
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vyome: $3.50
• High Price Target: $3.50
• Low Price Target: $3.50
• Potential Upside/Downside: +67.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.26 million
• Net Margins: -3,024.84%
• Pretax Margin: -3,097.87%
• Return on Equity: -197.33%
• Return on Assets: -138.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.37
• Quick Ratio: 4.37

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 45.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 3.12

Miscellaneous

• Outstanding Shares: 7,020,000
• Free Float: 4,702,000
• Market Cap: $14.67 million
• Optionable: N/A
• Beta: 1.53